OpenBilldrug price receipt

NADAC week of 2026-10-14

EXEMESTANE 25 MG TABLET

For 30 tablets

Pharmacies pay

$22.43 filed

30 × $0.74782 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$73.36 filed

30 × $2.44521 per EA, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18


The spread

3.3× estimated

Medicare paid 3.3× what pharmacies pay.

Part D averages every strength and form sold under “Exemestane” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$30.79 estimated

$22.43 + $3.36 (15%) + $5.00 fee per fill = $30.79

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

EXEMESTANE 25 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as exemestane.

FDA gives its dosage form as “tablet”, “tablet, film coated” and “tablet, sugar coated” and its route as oral.

FDA lists 8 labelers (the companies named on the label) for its NDCs, among them Upsher-Smith Laboratories, Inc., Breckenridge Pharmaceutical, Inc. and Aurobindo Pharma Limited.

FDA’s Established Pharmacologic Class for it is Aromatase Inhibitor.

The NADAC file of 2026-10-14 prices it under 9 NDCs (National Drug Codes); the FDA directory lists 8 of them.

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $22.43 for 30 tablets (30 × $0.74782 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 6, the CMS Covered Outpatient Drug Product File S/I/N drug category was not applied when grouping drugs for the calculation.

The 8 labelers

LabelerNDCsPharmacies pay per unit
Aurobindo Pharma Limited1$0.74782 per EA filed
Breckenridge Pharmaceutical, Inc.1$0.74782 per EA filed
Cipla USA Inc.1$0.74782 per EA filed
Florida Pharmaceutical Products, LLC1$0.74782 per EA filed
Mylan Pharmaceuticals Inc.1$0.74782 per EA filed
NorthStar Rx LLC1$0.74782 per EA filed
Upsher-Smith Laboratories, Inc.1$0.74782 per EA filed
Zydus Pharmaceuticals USA Inc.1$0.74782 per EA filed
Not listed as a package in the FDA directory1$0.74782 per EA filed
All 9 NDCs, with labeler and price
  • 00054-0080-13 · not listed as a package in the FDA directory · $0.74782 per EA · eff. 2026-09-23 filed
  • 00832-0595-30 · Upsher-Smith Laboratories, Inc. · $0.74782 per EA · eff. 2026-09-23 filed
  • 51991-0005-90 · Breckenridge Pharmaceutical, Inc. · $0.74782 per EA · eff. 2026-09-23 filed
  • 59651-0516-30 · Aurobindo Pharma Limited · $0.74782 per EA · eff. 2026-09-23 filed
  • 59762-2858-01 · Mylan Pharmaceuticals Inc. · $0.74782 per EA · eff. 2026-09-23 filed
  • 68382-0383-06 · Zydus Pharmaceuticals USA Inc. · $0.74782 per EA · eff. 2026-09-23 filed
  • 69097-0316-02 · Cipla USA Inc. · $0.74782 per EA · eff. 2026-09-23 filed
  • 71921-0190-33 · Florida Pharmaceutical Products, LLC · $0.74782 per EA · eff. 2026-09-23 filed
  • 72603-0329-01 · NorthStar Rx LLC · $0.74782 per EA · eff. 2026-09-23 filed

Other strengths, forms and brands

1 other product in the NADAC file shares the FDA nonproprietary name exemestane with EXEMESTANE 25 MG TABLET.

ProductPharmacies pay per unitMedicare per unit
AROMASIN 25 MG TABLET
brand · tablet
$38.97921 per EA filed
eff. 2026-01-01
$36.85009 per EA filed
Part D 2024 average
EXEMESTANE 25 MG TABLET this page
generic · tablet / tablet, film coated / tablet, sugar coated
$0.74782 per EA filed
eff. 2026-09-23
$2.44521 per EA filed
Part D 2024 average

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-01, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 9 NDCs’ NADAC prices is $0.74782 per EA filed.

Of the 5 other products in FDA’s Aromatase Inhibitor class priced per EA, 3 have a higher middle NADAC price and 2 a lower one. The one in the middle is FEMARA 2.5 MG TABLET, at $27.11602 per EA filed (eff. 2026-01-07).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-07, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What Medicare paid

Medicare Part D paid $73.36 for 30 tablets, at an average of $2.44521 per EA in 2024 (2024-01-01 to 2024-12-31) for “Exemestane”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 212,206 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why is the comparison with Medicare for EXEMESTANE 25 MG TABLET labelled estimated?
Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Exemestane / Exemestane: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on generic name.